RBC Capital Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $155
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Lisa Walter maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $135 to $155.
RBC Capital analyst Lisa Walter maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $135 to $155.